JPWO2023097276A5 - - Google Patents
Info
- Publication number
- JPWO2023097276A5 JPWO2023097276A5 JP2024531094A JP2024531094A JPWO2023097276A5 JP WO2023097276 A5 JPWO2023097276 A5 JP WO2023097276A5 JP 2024531094 A JP2024531094 A JP 2024531094A JP 2024531094 A JP2024531094 A JP 2024531094A JP WO2023097276 A5 JPWO2023097276 A5 JP WO2023097276A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- administered
- pharma
- fesoterodine
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283140P | 2021-11-24 | 2021-11-24 | |
| US63/283,140 | 2021-11-24 | ||
| US202263416745P | 2022-10-17 | 2022-10-17 | |
| US63/416,745 | 2022-10-17 | ||
| PCT/US2022/080429 WO2023097276A1 (en) | 2021-11-24 | 2022-11-23 | Methods of treating neurological disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024541770A JP2024541770A (ja) | 2024-11-12 |
| JP2024541770A5 JP2024541770A5 (https=) | 2025-07-16 |
| JPWO2023097276A5 true JPWO2023097276A5 (https=) | 2025-07-16 |
Family
ID=86540399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531094A Pending JP2024541770A (ja) | 2021-11-24 | 2022-11-23 | 神経障害の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250032460A1 (https=) |
| EP (1) | EP4436564A4 (https=) |
| JP (1) | JP2024541770A (https=) |
| KR (1) | KR20240110642A (https=) |
| AU (1) | AU2022396530A1 (https=) |
| CA (1) | CA3239067A1 (https=) |
| IL (1) | IL313067A (https=) |
| MX (1) | MX2024006371A (https=) |
| WO (1) | WO2023097276A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3061821T (pt) * | 2009-07-22 | 2019-09-05 | PureTech Health LLC | Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos |
| US8853219B2 (en) * | 2010-01-11 | 2014-10-07 | Neurosolis, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| WO2012033956A1 (en) * | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
| US9012489B2 (en) * | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| CA2978214A1 (en) * | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
-
2022
- 2022-11-23 MX MX2024006371A patent/MX2024006371A/es unknown
- 2022-11-23 AU AU2022396530A patent/AU2022396530A1/en active Pending
- 2022-11-23 IL IL313067A patent/IL313067A/en unknown
- 2022-11-23 JP JP2024531094A patent/JP2024541770A/ja active Pending
- 2022-11-23 US US18/712,916 patent/US20250032460A1/en active Pending
- 2022-11-23 CA CA3239067A patent/CA3239067A1/en active Pending
- 2022-11-23 EP EP22899553.6A patent/EP4436564A4/en active Pending
- 2022-11-23 WO PCT/US2022/080429 patent/WO2023097276A1/en not_active Ceased
- 2022-11-23 KR KR1020247020828A patent/KR20240110642A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002662A5 (https=) | ||
| JP2022191257A5 (https=) | ||
| JP2505944B2 (ja) | （Ｓ）―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物 | |
| JP2026035701A5 (https=) | ||
| JPH05163139A (ja) | 抗動脈硬化剤 | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JPWO2020257671A5 (https=) | ||
| JP2002544227A5 (https=) | ||
| JP2019531286A5 (https=) | ||
| JPWO2023078333A5 (https=) | ||
| JP2022177119A5 (https=) | ||
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| EP1345610B1 (en) | Quetiapine for treating of dyskinesia in non-psychotic patients | |
| JPWO2023097276A5 (https=) | ||
| JP2021530568A5 (https=) | ||
| JPWO2019234240A5 (https=) | ||
| JPWO2021089678A5 (https=) | ||
| JPWO2020023324A5 (https=) | ||
| CA2869243C (en) | Composition for the treatment of inflammatory and immune disorders | |
| JPWO2021087432A5 (https=) | ||
| JP2021521227A5 (https=) | ||
| JPWO2022093724A5 (https=) | ||
| JPWO2023107697A5 (https=) | ||
| JPWO2022101395A5 (https=) | ||
| HU227813B1 (en) | Pharmaceutical composition for the treatment of psychosis |